Cytokinetics Inc. Stock
Cytokinetics Inc. Stock
The price for the Cytokinetics Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.500 (-0.870%).
With 34 Buy predictions and not a single Sell prediction Cytokinetics Inc. is an absolute favorite of our community.
With a target price of 74 € there is a positive potential of 30.97% for Cytokinetics Inc. compared to the current price of 56.5 €.
So far the community has only identified positive things for Cytokinetics Inc. stock. The most positive votes were given for criterium "Worthwhile Investment for the next years".
Pros and Cons of Cytokinetics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Cytokinetics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Cytokinetics Inc. | -0.870% | -2.542% | 10.577% | 17.347% | 26.652% | 40.931% | 285.906% |
| Ardelyx Inc. | -0.470% | -3.964% | 1.395% | -6.825% | -0.463% | 180.604% | -5.108% |
| Krystal Biotech | 5.350% | 0.793% | 7.744% | 6.689% | 25.230% | 150.789% | - |
| Evolus Inc | 0.890% | -4.274% | 0.901% | -54.098% | -46.667% | -18.248% | 84.697% |
Comments
Cytokinetics (NASDAQ:CYTK) had its price target raised by analysts at Royal Bank Of Canada from $82.00 to $87.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at B. Riley. They now have a $90.00 price target on the stock, up previously from $80.00.
Show more
Ratings data for CYTK provided by MarketBeat
Cytokinetics (NASDAQ:CYTK) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Show more
Ratings data for CYTK provided by MarketBeat
News
CYTK Earnings Jump 3,065%
Cytokinetics (NASDAQ:CYTK), a late-stage biopharmaceutical company focused on cardiovascular disease, reported earnings for Q2 FY2025 on August 7, 2025. The headline news was a dramatic
